Who Is a Good Candidate for GLP-1 Medications? [2026] Eligibility Guide

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication. Some links in this article may be affiliate links, meaning we earn a small commission at no extra cost to you.

Over 42% of American adults meet the clinical definition of obesity, according to CDC data. Tens of millions more fall into the overweight category with at least one comorbidity. That means a staggering number of people could qualify for GLP-1 medications — but most don't know if they're actually a good candidate.

The eligibility landscape shifted dramatically in 2025 and into 2026. New FDA indications, expanded insurance coverage, the Medicare GLP-1 Bridge program, and next-generation drugs like retatrutide have widened the pool of who can access these treatments. But wider access doesn't mean universal access. Your BMI, medical history, current medications, and even your insurance plan all factor into whether a GLP-1 is right for you.

This guide breaks down every eligibility criterion you need to know — from the hard FDA cutoffs to the softer clinical judgment calls your doctor will make. If you've been wondering whether you qualify, this is the most comprehensive answer available in 2026.

If you're brand new to this drug class, start with our GLP-1 Medications for Beginners guide first. It covers the basics of how these medications work before diving into who should take them.

The Core FDA Eligibility Criteria: BMI Thresholds Explained

The FDA uses Body Mass Index as the primary gatekeeper for GLP-1 prescriptions. It's not the only factor — but it's the first one every provider checks.

BMI of 30 or Higher (Obesity)

If your BMI is 30 or above, you meet the threshold for a GLP-1 prescription for weight management without needing any additional qualifying conditions. This applies to medications like Wegovy (semaglutide) and Zepbound (tirzepatide), both FDA-approved specifically for chronic weight management.

To put that in real numbers: a 5'6" person weighing 186 pounds has a BMI of exactly 30. A 5'10" person hits that mark at 209 pounds. These aren't extreme weights — they describe a huge portion of the American population.

According to CDC National Health and Nutrition Examination Survey data, approximately 42.4% of U.S. adults have a BMI of 30 or higher. That's roughly 110 million people who meet this single criterion alone.

BMI of 27–29.9 (Overweight) Plus a Comorbidity

You don't need to be in the obesity category to qualify. The FDA also approves GLP-1 medications for adults with a BMI between 27 and 29.9 — if they have at least one weight-related health condition. Qualifying comorbidities include:

Type 2 diabetes — the original indication for drugs like Ozempic and Mounjaro
Hypertension (high blood pressure)
Dyslipidemia (high cholesterol or triglycerides)
Obstructive sleep apnea
Cardiovascular disease or history of cardiac events
Non-alcoholic fatty liver disease (NAFLD) or its more severe form, MASH
Osteoarthritis exacerbated by excess weight

An estimated 30.7% of U.S. adults fall in the overweight BMI range. Among them, the prevalence of at least one comorbidity is exceptionally high — some studies estimate 70-80% of overweight adults have hypertension, dyslipidemia, or pre-diabetes. The practical result: most overweight adults likely qualify on paper.

The BMI Limitation Everyone Should Know

BMI is a crude tool. It doesn't distinguish between muscle mass and fat mass. It doesn't account for where fat is distributed (visceral vs. subcutaneous). And it systematically miscategorizes certain populations — particularly Black, Asian, and Hispanic individuals whose metabolic risk profiles don't align neatly with BMI cutoffs.

Many clinicians in 2026 are increasingly willing to consider patients slightly below the BMI 27 threshold if waist circumference, body composition scans, or metabolic markers suggest elevated risk. The American Medical Association officially recognized BMI's limitations in 2023, and that policy shift is gradually changing clinical practice.

Your doctor may also use waist-to-hip ratio, DEXA body composition scans, or metabolic blood panels alongside BMI to build a fuller picture. If you're close to the threshold, don't assume you're automatically disqualified — have the conversation.

Type 2 Diabetes: The Original GLP-1 Indication

GLP-1 receptor agonists weren't invented for weight loss. They were developed as diabetes medications, and that remains a primary indication with its own eligibility pathway.

How Diabetes Changes Eligibility

If you have type 2 diabetes, BMI requirements effectively become secondary. Ozempic (semaglutide 0.5mg/1mg/2mg) and Mounjaro (tirzepatide) are FDA-approved for glycemic control in type 2 diabetes regardless of BMI. You could have a BMI of 25 — technically "normal weight" — and still receive a prescription if your A1C or blood glucose levels warrant treatment.

Approximately 38.4 million Americans have type 2 diabetes, according to the CDC. Another 97.6 million have pre-diabetes. The diabetes pathway is how many patients first access GLP-1 medications, and it's the indication most commonly covered by insurance.

A1C Thresholds Providers Typically Use

While the FDA doesn't set a specific A1C cutoff for GLP-1 prescriptions, most providers follow American Diabetes Association (ADA) guidelines:

A1C of 7.0% or higher on metformin alone — GLP-1s are frequently added as second-line therapy
A1C of 8.0% or higher — many endocrinologists will consider GLP-1s as first-line alongside or instead of metformin
A1C of 9.0% or higher — aggressive intervention is typically warranted, and injectable GLP-1s are strongly considered

The 2026 ADA Standards of Care position GLP-1 receptor agonists as preferred second-line agents after metformin, particularly for patients with established cardiovascular disease or high cardiovascular risk. This is a meaningful shift from five years ago, when sulfonylureas and other older drugs dominated second-line treatment.

Pre-Diabetes and the Medicare Expansion

Pre-diabetes is where 2026 eligibility gets interesting. The new Medicare GLP-1 Bridge program, announced by CMS in December 2025 and launching in July 2026, explicitly includes pre-diabetes as a qualifying condition for Medicare beneficiaries with BMI ≥27. This is a first — Medicare previously excluded anti-obesity medications from Part D coverage entirely.

Qualifying conditions under the Medicare Bridge include:

Pre-diabetes (as defined by ADA guidelines — fasting glucose 100-125 mg/dL or A1C 5.7-6.4%)
Previous myocardial infarction (heart attack)
Previous stroke
Symptomatic peripheral artery disease

The BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model follows the Bridge and adds additional qualifying conditions like obstructive sleep apnea and MASH with liver fibrosis. If you're a Medicare beneficiary, this is a game-changer for access.

Cardiovascular Risk: The Expanding Indication

Weight loss was GLP-1 medications' breakout moment. But cardiovascular protection may be their most important long-term indication — and it's reshaping who qualifies.

The SELECT Trial and Its Impact

The landmark SELECT trial, published in 2023, demonstrated that semaglutide 2.4mg (Wegovy) reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease — even in participants without diabetes. This led the FDA to approve Wegovy for cardiovascular risk reduction in March 2024, a first for any anti-obesity medication.

What this means for eligibility: if you have a history of heart attack, stroke, or peripheral artery disease and a BMI ≥27, you now have a cardiovascular indication for GLP-1 therapy — separate from and in addition to the weight management indication. This can change how your insurance views the prescription. Some plans that deny "weight loss drugs" will cover the same medication for cardiovascular risk reduction.

Who Qualifies Under the Cardiovascular Indication

The FDA's cardiovascular indication for Wegovy covers adults who:

Have established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease)
Have a BMI of 27 or higher
May or may not have type 2 diabetes — the SELECT trial included both groups

Notably, this indication does not require obesity (BMI ≥30). The lower BMI ≥27 threshold applies, and you don't need a separate comorbidity beyond the cardiovascular disease itself, since that is the indication.

Heart Failure and Emerging Evidence

Beyond atherosclerotic cardiovascular disease, 2025 data from the STEP-HFpEF trials showed semaglutide improved symptoms, physical limitations, and exercise function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. While not yet a formal FDA indication, many cardiologists are prescribing GLP-1s off-label for HFpEF patients who meet the weight criteria.

If you have heart failure and obesity, ask your cardiologist specifically about this data. The evidence is strong enough that major cardiology guidelines are beginning to incorporate it.

For a deep comparison of the two most-prescribed GLP-1 options for cardiovascular patients, see our Semaglutide vs Tirzepatide: Head-to-Head [2026] breakdown.

Who Should NOT Take GLP-1 Medications: Contraindications and Cautions

Not everyone who meets the BMI threshold is a good candidate. Some conditions are absolute deal-breakers. Others require careful risk-benefit analysis with your doctor.

Absolute Contraindications

The FDA identifies several conditions where GLP-1 medications should not be prescribed:

Personal or family history of medullary thyroid carcinoma (MTC). In animal studies, GLP-1 receptor agonists caused thyroid C-cell tumors in rodents. While human data hasn't confirmed this risk, the FDA applies a precautionary Black Box Warning. If you or a blood relative have had MTC, GLP-1s are off the table.

Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This rare genetic condition predisposes people to MTC. Patients with MEN2 are categorically excluded.

Known hypersensitivity. If you've had an allergic reaction to semaglutide, tirzepatide, or any component of the formulation, you cannot use that specific medication. Cross-reactivity between different GLP-1s is possible but not guaranteed — your doctor may try an alternative.

Pregnancy and breastfeeding. GLP-1 medications are Category X or have insufficient safety data in pregnancy. You must discontinue at least 2 months before a planned pregnancy (6-10 weeks for longer-acting formulations like tirzepatide due to its half-life). If you become pregnant while on a GLP-1, stop immediately and contact your provider.

Strong Cautions (Not Absolute, But Serious)

History of pancreatitis. GLP-1 medications carry a warning for acute pancreatitis. If you've had pancreatitis before, most providers will either avoid GLP-1s or monitor you very closely with regular lipase levels.

Severe gastroparesis. GLP-1s slow gastric emptying — that's partly how they work. If you already have significantly delayed gastric emptying, these drugs can worsen it to the point of hospitalization. Mild gastroparesis may be manageable, but severe cases are generally excluded.

Active gallbladder disease. Rapid weight loss from any cause increases gallstone risk. GLP-1 medications add to that risk. If you have active gallbladder issues, your doctor may want those resolved before starting treatment.

Severe kidney impairment. Semaglutide and tirzepatide are not primarily renally cleared, but dehydration from nausea and vomiting (common side effects) can stress compromised kidneys. Patients with eGFR below 15 mL/min or on dialysis need very careful evaluation.

Active or recent eating disorder. This is nuanced. Some clinicians see GLP-1 medications as potentially helpful for binge eating disorder. Others worry about reinforcing restrictive patterns in patients with anorexia or bulimia history. There's no FDA guidance here — it's a clinical judgment call, and a good provider will screen for disordered eating before prescribing.

Medication Interactions to Know About

GLP-1 medications interact meaningfully with several drug classes:

Insulin and sulfonylureas — combining these with GLP-1s increases hypoglycemia risk; doses usually need reduction
Oral contraceptives — delayed gastric emptying may reduce absorption; barrier methods may be recommended as backup
Warfarin — INR monitoring may be needed during initiation
Oral medications with narrow therapeutic windows — absorption timing can shift; your pharmacist should review your full medication list

Age, Adolescents, and Older Adults: Special Populations

GLP-1 eligibility isn't one-size-fits-all across age groups. Different life stages bring different considerations.

Adults 18-64: The Standard Population

This is the most straightforward group. Standard BMI criteria apply. Most clinical trial data comes from this age range. If you're 18-64, meet the BMI threshold, and don't have contraindications, you're a textbook candidate.

Within this group, the strongest candidates tend to be those who have:

Tried lifestyle modifications (diet, exercise) for at least 3-6 months without reaching target weight loss
A stable medical history that doesn't include contraindications
Realistic expectations — GLP-1s typically produce 15-22% total body weight loss over 12-18 months
A plan for long-term use or a structured discontinuation strategy, since weight regain after stopping is common

Adolescents (12-17): Limited but Growing Approval

Wegovy received FDA approval for adolescents aged 12+ with obesity (BMI ≥95th percentile for age and sex) in December 2022. The STEP TEENS trial showed semaglutide produced a mean body weight change of -16.1% vs. +0.6% with placebo in adolescents over 68 weeks.

Zepbound was approved for adolescents 12 and older in late 2024 based on similarly strong trial data.

Key differences for adolescent candidates:

BMI is assessed using age- and sex-specific growth charts, not the adult cutoffs
Parental or guardian consent is required
Most guidelines recommend attempting structured lifestyle intervention first
Long-term effects on growth, bone density, and development are still being studied
Prescribing is typically managed by pediatric endocrinologists or obesity medicine specialists, not general practitioners

Older Adults (65+): No Upper Age Limit, But More Nuance

There is no FDA-imposed upper age limit for GLP-1 medications. Adults over 65 were included in major clinical trials. But the risk-benefit calculation shifts.

Concerns specific to older candidates:

Muscle mass loss (sarcopenia) — GLP-1-induced weight loss includes lean mass, and older adults already lose muscle with aging. Resistance training and adequate protein intake (1.0-1.2 g/kg/day) become critical. Read our guide on preventing muscle loss on GLP-1 medications.
Fall risk — reduced muscle mass plus potential dizziness or dehydration from side effects can increase falls
Nutritional adequacy — reduced appetite can lead to insufficient nutrient intake in populations already at risk for deficiencies
Polypharmacy — older adults take more medications, increasing interaction risk
Slower GI motility — age-related slowing of gastric emptying may amplify GLP-1 side effects

That said, the cardiovascular and metabolic benefits can be enormous for older adults. A 70-year-old with obesity, type 2 diabetes, and cardiovascular disease is a strong candidate for the right GLP-1 — the benefits almost certainly outweigh the risks with proper monitoring.

Insurance, Cost, and Practical Eligibility in 2026

Meeting the medical criteria is only half the battle. Whether you can actually access a GLP-1 often depends on your insurance, your budget, and your willingness to navigate prior authorization.

Commercial Insurance: Prior Authorization Hurdles

Most commercial insurance plans cover GLP-1 medications for type 2 diabetes. Coverage for weight management is more variable. Typical prior authorization requirements include:

Documented BMI meeting the FDA threshold (30+ or 27+ with comorbidity)
Failed lifestyle intervention — usually 3-6 months of documented diet and exercise attempts
Provider documentation of the weight-related comorbidity
Step therapy — some plans require trying (and failing) older, cheaper medications first (like orlistat or phentermine)

Denial rates remain frustratingly high. Industry data suggests 30-50% of initial GLP-1 prior authorizations are denied, though many are overturned on appeal. If you're denied, appeal. If the appeal fails, ask your doctor to submit under a different indication (e.g., cardiovascular risk reduction instead of weight management for the same drug).

Medicare: The 2026 Breakthrough

Historically, Medicare Part D excluded anti-obesity medications entirely. The Treat and Reduce Obesity Act never passed Congress, leaving millions of Medicare beneficiaries without coverage.

That changed with the Medicare GLP-1 Bridge, launching July 2026. Eligible drugs under the Bridge include:

Foundayo (the new semaglutide formulation)
Wegovy (injection and oral tablets)
Zepbound (KwikPen formulation)

To qualify, Medicare beneficiaries need BMI ≥27 plus one of: pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease. The follow-on BALANCE Model expands conditions further to include sleep apnea, MASH, and a BMI ≥35 with lifestyle modification attempts.

This is the biggest shift in GLP-1 access in years. If you're on Medicare, talk to your provider now about documentation so you're ready when the program launches.

The Cost Factor Without Insurance

If you don't have coverage, brand-name GLP-1 medications run roughly $900-$1,350 per month at retail. That prices out most people. But 2026 offers more options than ever:

Compounded semaglutide — available through telehealth platforms and compounding pharmacies, often $150-$400/month. But the regulatory landscape is evolving rapidly. Check our Compounded vs Brand Name GLP-1 [2026] guide for the latest legality and safety analysis.
Manufacturer savings programs — Novo Nordisk and Eli Lilly both offer savings cards that can reduce out-of-pocket costs for commercially insured patients
Generic semaglutide — emerging in some markets, though availability and pricing vary

Cost shouldn't be the sole determinant of candidacy, but it's naive to ignore it. The best candidate in the world can't benefit from a drug they can't afford or access.

The Clinical Assessment: What Your Doctor Actually Evaluates

You know the FDA criteria. But what happens when you actually sit in the exam room? Providers evaluate several dimensions beyond just BMI.

Medical History Deep Dive

Your provider will review:

Weight history — Have you been obese your entire adult life, or is this recent? Patterns matter for treatment planning
Previous weight loss attempts — What have you tried? Diets, exercise programs, other medications, bariatric surgery? This documents "failed lifestyle modification" for insurance and helps your doctor understand your relationship with weight management
Family history — Obesity, diabetes, cardiovascular disease, and thyroid cancer in first-degree relatives all influence the decision
Mental health history — Depression, anxiety, binge eating disorder, and other conditions can affect treatment choice and monitoring needs
Surgical history — Prior bariatric surgery, thyroid surgery, or GI procedures may affect GLP-1 eligibility or dosing

Lab Work and Screening

Before prescribing, most providers will order:

A1C and fasting glucose — to screen for diabetes or pre-diabetes
Lipid panel — cholesterol and triglycerides establish cardiovascular risk
Thyroid function tests — TSH and calcitonin (the latter screens for medullary thyroid carcinoma)
Liver function tests — ALT, AST to evaluate for NAFLD/MASH
Kidney function — eGFR and creatinine
Metabolic panel — electrolytes, especially if you have kidney concerns
Pregnancy test — for women of childbearing age

Some providers also order body composition analysis (DEXA scan) to establish a baseline for tracking fat vs. lean mass changes during treatment.

The Readiness Assessment

Good providers evaluate psychological and practical readiness:

Can you commit to the injection schedule? Weekly injections require consistency
Are you prepared for dietary changes? GLP-1s reduce appetite, but you still need to make nutritious food choices with the smaller amount you eat
Do you understand this is likely long-term? Weight regain after discontinuation averages two-thirds of lost weight within a year. Most patients need to plan for ongoing treatment
Can you afford it? Providers should discuss cost openly, including alternatives if brand-name medications aren't financially sustainable
Are you willing to add exercise? Resistance training in particular protects against muscle loss — the most significant concern with GLP-1-induced weight loss

Choosing the Right GLP-1 Medication

Not every GLP-1 is the same. Your provider will match you to a specific drug based on your profile:

Primary goal is diabetes management → Ozempic or Mounjaro
Primary goal is weight loss → Wegovy or Zepbound
Both diabetes and weight loss → Mounjaro or tirzepatide-based options, which act on both GLP-1 and GIP receptors
Cardiovascular risk reduction → Wegovy, based on SELECT trial data
Needle-averse patients → Oral semaglutide (Rybelsus for diabetes; oral Wegovy tablets approved for weight management)
Looking toward next-gen options → Retatrutide, a triple agonist (GLP-1/GIP/glucagon), is in Phase 3 trials with promising efficacy data showing up to 24% body weight reduction

For a detailed comparison of the two most popular options, read Semaglutide vs Tirzepatide: Head-to-Head [2026].

Self-Assessment: Are You a Good Candidate?

Before your appointment, run through this checklist honestly. It won't replace your doctor's evaluation, but it gives you a realistic picture of where you stand.

Strong Candidate Indicators

You're likely a good candidate if three or more of these apply:

Yellow Flags (Proceed with Caution)

These don't disqualify you but require extra discussion with your provider:

History of gallbladder disease or gallstones
Current eating disorder or history of disordered eating
Severe kidney disease (eGFR < 30)
Gastroparesis or chronic severe nausea
Current use of insulin or sulfonylureas (dose adjustments needed)
Age over 75 (higher sarcopenia risk)
BMI just under 27 but with metabolic risk markers
Planning a surgical procedure in the near future (some surgeons require discontinuation before anesthesia due to gastric emptying concerns)

Red Flags (Likely Disqualified)

If any of these apply, a GLP-1 is almost certainly not appropriate:

Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Active pregnancy or breastfeeding
Previous severe allergic reaction to a GLP-1 medication
Active severe pancreatitis
End-stage kidney disease on dialysis (case-by-case, but generally excluded)

Frequently Asked Questions

Can I get a GLP-1 prescription if my BMI is under 27?

Currently, the FDA does not approve GLP-1 medications for weight management in patients with BMI below 27. However, if you have type 2 diabetes, BMI is not a strict criterion for GLP-1 prescriptions aimed at glycemic control. Some providers may prescribe off-label in certain circumstances, but insurance is unlikely to cover it, and you'd be paying out of pocket.

Do I need to try diet and exercise first before qualifying?

Most insurance companies require documentation of "failed lifestyle modification" — typically 3-6 months of a supervised or structured diet and exercise program. The FDA itself doesn't require this, but your insurer probably does. Even without the insurance requirement, GLP-1 medications work best alongside healthy eating and regular physical activity, not instead of them.

Can I take GLP-1 medications if I've had bariatric surgery?

It depends on the type of surgery. Roux-en-Y gastric bypass patients may have altered drug absorption. Sleeve gastrectomy patients generally tolerate GLP-1s, and some bariatric surgeons prescribe them for patients who've regained weight after surgery. There is growing evidence supporting this use, but it's considered off-label. Your bariatric surgeon and prescribing provider should coordinate.

How long do I need to take a GLP-1 medication?

Current evidence suggests GLP-1 medications work as long as you take them. The STEP 1 extension trial showed participants regained approximately two-thirds of lost weight within one year of stopping semaglutide. Most obesity medicine specialists now frame GLP-1 therapy as a long-term or potentially lifelong treatment — similar to how blood pressure or cholesterol medications are managed. Some patients successfully taper to lower maintenance doses after reaching their target weight.

Will the new Medicare GLP-1 Bridge cover my medication?

If you're a Medicare beneficiary, you may qualify starting July 2026 if you have BMI ≥27 and at least one of these conditions: pre-diabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease. Covered medications include Foundayo, Wegovy (injection and oral), and Zepbound KwikPen. Talk to your provider now about documenting your qualifying conditions so you're ready when the program launches.

Quick Answer